Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from single-arm phase 2 trials, with complete responses (CRs) in 40%...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Sermer, David, Batlevi, Connie, Palomba, M. Lia, Shah, Gunjan, Lin, Richard J., Perales, Miguel-Angel, Scordo, Michael, Dahi, Parastoo, Pennisi, Martina, Afuye, Aishat, Silverberg, Mari Lynne, Ho, Caleb, Flynn, Jessica, Devlin, Sean, Caron, Philip, Hamilton, Audrey, Hamlin, Paul, Horwitz, Steven, Joffe, Erel, Kumar, Anita, Matasar, Matthew, Noy, Ariela, Owens, Colette, Moskowitz, Alison, Straus, David, von Keudell, Gottfried, Rodriguez-Rivera, Ildefonso, Falchi, Lorenzo, Zelenetz, Andrew, Yahalom, Joachim, Younes, Anas, Sauter, Craig
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556134/
https://ncbi.nlm.nih.gov/pubmed/33002134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002118
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky